Skip to Main content Skip to Navigation
Journal articles

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study

Abstract : Background and Aim In patients with inflammatory bowel disease (IBD) tolerating 2-h infusions of 5 mg/kg infliximab scheduled maintenance therapy, the infusion time can be shortened to 1-h with good tolerability. A retrospective study with small sample size demonstrated the feasibility of 1-hour infusion time for 10 mg/kg infliximab in IBD patients. Methods Between November 2011 and July 2012, 63 patients received 1-hour 10 mg/kg infliximab infusions under standard operating procedures and were enrolled in a prospective observational study. Intravenous steroid premedication was given to all patients. Results Sixty-three IBD patients on infliximab maintenance therapy (43 Crohn's disease, 34 males) received 1-hour 10 mg/kg infusions during the study period. A total of 182 infliximab infusions were administered. Seventeen (26%) patients were receiving concomitant immunomodulators. Two patients experienced (2/182, 1%) severe acute infusion reactions consisting on a cutaneous lupus and one severe anaphylactic reaction. We also observed one (1/182, 0.5%) severe delayed reaction after the first 1-hour infliximab infusion consisting on acne generalis. All 3 reactions led to infliximab discontinuation. No mild acute reactions and 6 mild delayed reactions (6/182, 3%) occurred. Conclusions In patients with IBD receiving infliximab scheduled maintenance therapy, 1-hour infusion time for 10 mg/kg infliximab seems to be well tolerated. This option might be considered in clinical practice in order to decrease the extra-burden of infliximab infusions in this patient population.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-01699626
Contributor : Ngere Ul <>
Submitted on : Friday, February 2, 2018 - 3:33:04 PM
Last modification on : Sunday, October 25, 2020 - 7:05:56 AM

Links full text

Identifiers

Citation

Abdenour Babouri, Xavier Roblin, Jérome Filippi, Xavier Hébuterne, Marc-André Bigard, et al.. Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study. Journal of Crohn's and Colitis, Elsevier - Oxford University Press, 2014, 8 (2), pp.161 - 165. ⟨10.1016/j.crohns.2013.08.004⟩. ⟨hal-01699626⟩

Share

Metrics

Record views

112